Skip to main content
EDX Medical Group Plc logo

EDX Medical Group Plc — Investor Relations & Filings

Ticker · EDX ISIN · GB00BNDMJS47 LEI · 213800BZVJZTMCZ6DJ63 Aquis Stock Exchange Human health and social work activities
Filings indexed 116 across all filing types
Latest filing 2025-02-20 Director's Dealing
Country GB United Kingdom
Listing Aquis Stock Exchange EDX

About EDX Medical Group Plc

https://edxmedical.com/

EDX Medical Group Plc develops and provides digital diagnostic products and services for healthcare professionals. Its solutions are designed for the rapid detection and characterization of major diseases, enabling personalized treatment and improved patient outcomes. The company's primary focus areas are oncology, cardiology, and infectious diseases. Key offerings in oncology include comprehensive tumour profiling using whole exome and transcriptome sequencing, liquid biopsy analysis, and functional ex vivo assays that predict tumour response to specific therapies. The company also develops highly sensitive tests for early detection of cancers such as prostate and testicular cancer. In infectious diseases, EDX Medical develops point-of-care multiplex tests for conditions like sepsis and pneumonia. The company's approach integrates advanced molecular biology, genomic sequencing, and digital technologies across its laboratory-based services and point-of-care devices.

Recent filings

Filing Released Lang Actions
Director dealing
Director's Dealing Classification · 100% confidence The document is an official announcement from EDX Medical Group PLC regarding a purchase of 20,000 ordinary shares by a director, Professor Sir Christopher Evans. The text explicitly uses the header 'DIRECTOR DEALING' and details the transaction date, price, and the resulting shareholding percentage. This fits the definition of a Director's Dealing (DIRS) filing.
2025-02-20 English
Director dealing
Director's Dealing Classification · 100% confidence The document is an official announcement titled 'DIRECTOR DEALING' from EDX Medical Group PLC. It details the purchase of 320,000 ordinary shares by Professor Sir Christopher Evans, a director of the company. This falls squarely under the definition of a Director's Dealing report, which tracks personal share transactions by company executives.
2025-02-19 English
Director dealing
Director's Dealing Classification · 100% confidence The document is an official announcement titled 'DIRECTOR DEALING' regarding share purchases by the CEO and a board director of EDX Medical Group PLC. It details the number of shares purchased, the price per share, and the resulting ownership percentages. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing, which reports personal share transactions by company executives.
2025-02-18 English
EDX develops new ‘super test’ for prostate cancer
Regulatory Filings Classification · 95% confidence The document is a press release issued via the Regulatory News Service (RNS) announcing a new product development ('super test' for prostate cancer) by EDX Medical Group PLC. It provides details on the technology, clinical validation, and future regulatory plans. As it is a corporate announcement regarding business operations and product development rather than a formal financial report, dividend notice, or governance filing, it falls under the general regulatory announcement category.
2025-02-17 English
Appointment of director & deputy chair
Board/Management Information Classification · 100% confidence The document is an official announcement from EDX Medical Group plc regarding the appointment of a new board director and deputy chair. It details the individual's background, the board's approval, and required regulatory disclosures regarding directorships. This fits the definition of a Board/Management Information filing (MANG).
2025-02-14 English
Interim Report: Six Months to Sep 30, 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report and Financial Statements for the six-month period ended 30 September 2024'. It contains comprehensive financial statements, including the Condensed Consolidated Statement of Comprehensive Income, Statement of Financial Position, and notes to the interim financial statements. It is not merely an announcement (RPA) as it provides the full interim financial data for the specified period. H1 2024
2024-12-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.